Last reviewed · How we verify

NCT04943926: CARBCOUNT

Dietary Strategies for Remission of Type 2 Diabetes

Recruiting now NA Last updated 8 July 2022
What this trial tests

NA trial testing Energy restricted diet in Diabetes Mellitus, Type 2 in 600 participants. Currently enrolling.

Timeline
4 January 2022
Primary endpoint
31 December 2024
31 December 2040

Quick facts

Lead sponsorUniversity of Bergen
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment600
Start date4 January 2022
Primary completion31 December 2024
Estimated completion31 December 2040
Sites1 location across Norway

Drugs / interventions tested

Conditions studied

Sponsor

University of Bergen

Who can join

Adults 24 to 70, any sex, with Diabetes Mellitus, Type 2 or Overweight and Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this project, the investigators will perform a multicenter randomised controlled trial to determine whether advice to consume a moderate, whole food-based low-carbohydrate high-fat (LCHF) ad libitum diet (CarbCount program) can produce and maintain equal remission rates of type 2 diabetes (T2D) as a nutritionally complete very-low-calorie formula diet followed by a energy-restrictive (i.e., calorie counting) diet (DiRECT principles). Within the principles of each approach, the dietary goals and change will be adjusted according to individual needs/capabilities conducive to long-term adherence. Furthermore, the investigators aim to determine whether the rate of diet-induced remission is reflected in/can be predicted by baseline or diet-induced changes in glucose variability (e.g., time-in-range measured by continuous glucose monitoring) and other factors such as anthropometric changes and genetic susceptibility. Each center will also conduct locally-lead standalone mechanistic research, including analyses of intra-abdominal/hepatic fat accumulation, adipose tissue biopsies and/or measurements of energy metabolism. Additionally, changes in medication use, nutritional status, cardiovascular disease risk, as well as adverse events, will be monitored.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Nutrition Interventions for Remission of Type 2 Diabetes: Potential Role for Diabetes-Specific Nutrition Formulas.
    Trenell M, Bajaj H, Mechanick JI, Hamdy O. · · 2025 · cited 1× · PMID 40290837 · DOI 10.2337/cd24-0052
  2. Tuned by time: the role of circadian rhythms in metabolic energy sensing and chronotherapy.
    Thanuskodi Rajakumar A, Kodiveri Muthukaliannan G. · · 2025 · PMID 41339276 · DOI 10.1080/07853890.2025.2596548

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

Other University of Bergen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04943926.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing